炎症性关节炎的中国患者中低于最佳的甲状腺素利用率:来自中国中心的数据
Qian Wang1, Yang Zhang2, Hua Zhang1
1Department of Rheumatology and Immunology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Clinical rheumatology
|August 6, 2025
概括
在患有炎症性关节炎的中国患者中,甲基 (MTX) 剂量往往不足,这可能会限制其有效性. 对于MTX的坚持率也低于最佳,影响了治疗结果.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 甲托雷克萨特 (MTX) 是炎症性关节炎的主要治疗方法.
- 低于最佳的MTX使用可能导致治疗反应不佳.
研究的目的:
- 为了研究MTX在炎症性关节炎的中国患者当前的使用模式.
- 确定与MTX剂量,坚持和副作用相关的问题.
主要方法:
- 在患有类风湿性关节炎 (RA) 或牛皮性关节炎 (PsA) 的门诊患者中进行了回顾性横截面调查.
- 收集的数据包括MTX剂量,组合疗法,副作用和坚持率.
- 调查问卷被用来收集有关当前和以前MTX使用的信息.
主要成果:
- 显著比例的RA (81.2%) 和PsA (80.4%) 患者在MTX.
- 平均MTX剂量为9.68毫克/周,范围为2.5-15毫克/周,表明潜在的剂量不足.
- 坚持率为RA的74.6%和PsA的74.4%;MTX撤销发生在18.8%-19.6%的患者中,主要是由于恶心和肝功能异常.
结论:
- 在炎症性关节炎的中国患者中,MTX剂量不足很普遍.
- 观察到低于最佳的MTX坚持率.
- 这些因素表明,MTX可能无法在这个人群中实现其全部治疗潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Inflammatory Bowel Disease IV: Pharmacological Management
190
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
190


